Humacyte (NASDAQ:HUMA) Stock Lifted to Hold by Barclays

Key Points

• Barclays upgraded Humacyte to “Hold,” while analysts remain mixed: six rate the stock Buy, one Hold, and one Sell. MarketBeat reports a consensus “Moderate Buy” rating with a $5.68 price target.
• HUMA shares opened at $0.47, near their 52-week low of $0.46, and have declined 1.2%. The company has a market capitalization of about $131.2 million.
• Humacyte reported a quarterly loss of $0.16 per share, missing estimates by $0.05, while revenue of $0.41 million fell short of the $1.04 million forecast. The biotechnology company is developing bioengineered human tissues, including its SYMVESS vascular graft.

Humacyte (NASDAQ:HUMA - Get Free Report) was upgraded by equities researchers at Barclays to a "hold" rating in a research note issued to investors on Wednesday, Zacks reports.

A number of other analysts have also commented on HUMA. HC Wainwright increased their price objective on Humacyte from $3.00 to $4.00 and gave the company a "buy" rating in a research note on Thursday, June 11th. Benchmark reduced their target price on shares of Humacyte from $2.00 to $1.00 and set a "speculative buy" rating on the stock in a report on Thursday, August 13th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Humacyte in a research note on Friday, October 2nd. BTIG Research reiterated a "buy" rating and set a $2.00 price target on shares of Humacyte in a report on Wednesday, August 12th. Finally, TD Cowen cut their price objective on shares of Humacyte from $1.50 to $1.25 and set a "buy" rating for the company in a research report on Wednesday, June 17th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $5.68.

Humacyte Trading Down 1.2%

Shares of HUMA opened at $0.47 on Wednesday. The company has a debt-to-equity ratio of 2.07, a current ratio of 6.21 and a quick ratio of 5.74. Humacyte has a 1-year low of $0.46 and a 1-year high of $1.90. The stock has a market cap of $131.20 million, a price-to-earnings ratio of -0.96 and a beta of 2.44. The firm has a 50 day simple moving average of $0.61 and a 200-day simple moving average of $0.77.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.05). Humacyte had a negative net margin of 4,556.29% and a negative return on equity of 983.32%. The company had revenue of $0.41 million for the quarter, compared to analyst estimates of $1.04 million. Equities analysts forecast that Humacyte will post -0.4 EPS for the current fiscal year.

Institutional Trading of Humacyte

Hedge funds have recently added to or reduced their stakes in the business. Beacon Pointe Advisors LLC bought a new stake in shares of Humacyte during the second quarter valued at approximately $28,000. R Squared Ltd increased its position in Humacyte by 140.5% in the 1st quarter. R Squared Ltd now owns 62,911 shares of the company's stock valued at $38,000 after acquiring an additional 36,758 shares during the period. Wealth Effects LLC increased its position in Humacyte by 33.6% in the 1st quarter. Wealth Effects LLC now owns 204,500 shares of the company's stock valued at $124,000 after acquiring an additional 51,433 shares during the period. Bank of New York Mellon Corp bought a new stake in Humacyte during the 2nd quarter valued at $44,000. Finally, Caitong International Asset Management Co. Ltd raised its stake in Humacyte by 841.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 70,414 shares of the company's stock valued at $68,000 after acquiring an additional 62,931 shares in the last quarter. 44.71% of the stock is owned by institutional investors and hedge funds.

About Humacyte

Humacyte, Inc is a biotechnology company developing and manufacturing bioengineered human tissues for use in regenerative medicine. Its technology platform is designed to produce off-the-shelf, implantable tissues that can be stored and transported for use when needed, potentially reducing reliance on tissue obtained directly from patients or human donors.

The company's primary product is SYMVESS, an acellular tissue-engineered vascular graft designed to replace or repair damaged blood vessels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.